CUMYL-PICA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | 1400742-32-6 |
| PubChem (CID) | 86273678 |
| ChemSpider | 34450887 |
| Chemical and physical data | |
| Formula | C23H28N2O |
| Molar mass | 348.49 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
CUMYL-PICA (SGT-56) is an indole-3-carboxamide based synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of SDB-006.[1] It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers.[2] CUMYL-PICA acts as a potent agonist for the cannabinoid receptors, with approximately 20x selectivity for CB1, having an EC50 of 0.66nM for human CB1 receptors and 13nM for human CB2 receptors.[3]
See also
References
- ↑ "CUMYL-PICA". Cayman Chemical. Retrieved 8 July 2015.
- ↑ The Risk Assessment Score Table. New Zealand Ministry of Health, 27 September 2013
- ↑ Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626. Retrieved 11 July 2015.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.